Nifedipine
Product Images NDC 50090-4249

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 50090-4249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image1 (Image 01)

FDA Label Image

Image2 (Image 02)

The text describes mean reductions in blood pressure (systolic/diastolic) for different doses of Nifedipine ER tablets in two studies. Study 1 included doses of 30mg, 60mg, and 90mg, while study 2 included the same doses. The number of patients (N) and the mean trough dose reduction is given for each dose. "Placebo response subtracted" is noted, and Nifedipine ER is defined as Nifedipine extended-release tablets.*

FDA Label Image

Image3 (Image 03)

This is a table that compares the percentage of adverse effects in patients taking Nifedipine extended-release tablets versus a placebo. The adverse effects are headache, flushing/heat sensation, dizziness, fatigue/asthenia, nausea, and constipation. The number of patients included was 370 for Nifedipine and 126 for the placebo.*

FDA Label Image

Label Image (Lbl500904249)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.